Karuna Therapeutics, Inc.
(NASDAQ : KRTX)

( )
KRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.05%134.770.7%$946.17m
BMYBristol-Myers Squibb Co.
-2.03%56.481.4%$867.08m
MRKMerck & Co., Inc.
0.64%84.670.7%$770.19m
PFEPfizer Inc.
1.21%37.670.9%$759.23m
ABBVAbbVie, Inc.
0.32%89.012.3%$692.82m
LLYEli Lilly & Co.
0.90%115.101.1%$416.14m
NVSNovartis AG
0.08%90.400.2%$158.81m
AZNAstraZeneca Plc
-0.56%47.671.2%$149.33m
RETAReata Pharmaceuticals, Inc.
-1.17%206.003.5%$139.55m
GSKGlaxoSmithKline Plc
0.37%44.500.2%$125.78m
KRTXKaruna Therapeutics, Inc.
29.16%123.990.0%$123.57m
NVONovo Nordisk A/S
-0.07%57.030.1%$81.42m
SNYSanofi
-1.05%46.220.2%$64.70m
RARXRa Pharmaceuticals, Inc.
-0.17%46.630.8%$36.59m
CNSTConstellation Pharmaceuticals, Inc.
2.17%40.010.0%$32.98m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.